SAN DIEGO--(BUSINESS WIRE)--MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that Jonathan R. T. Lakey, PhD is no longer the Company’s president and chief scientific officer. Dr. Lakey remains a member of the Board of Directors.
